agreed to buy privately held
in a stock deal worth $225 million.
The acquisition, which will be accounted for as a pooling of interests, is expected to be neutral to earnings in the first year after the deal is closed and accretive thereafter, according to Medtronic.
PercuSurge will join the Medtronic Vascular unit. Medtronic said the acquisition will enhance its interventional vascular product offerings and add innovations designed to reduce complications in the treatment of vascular disease.